Загрузка видео...

Не удалось загрузить видео

На главную

Fantastic news for genome engineers: Bridge recombinases work in human cells!!🧬 And they can make really big insertions, deletions, and inversions with impressive efficiency. From Arc Institute Patrick Hsu Nicholas Perry & team

16,353 просмотров • 1 год назад •via X (Twitter)

Комментарии: 3

Фото профиля Julia Bauman
Julia Bauman1 год назад

The preprint: The tweetorial:

Фото профиля Julia Bauman
Julia Bauman1 год назад

The STICHR video:

Фото профиля ksminnovation
ksminnovation1 год назад

AI is transforming healthcare! A KSM-led study shows AI can detect Celiac disease 4 years earlier @TalPatalon @MedPredict

Похожие видео

🚨ImmunityBio’s Anktiva: A New FDA-Approved Immunotherapy for certain bladder cancer. They are also developing treatments that may reduce the need for strong chemo, for blood cancer, lung cancer, brain cancer, and more. Broader approvals may take time. Someone call the President and fast-track this. Dr. Pat Soon-Shiong leads development beyond typical biotech efforts. Most cancer medicines, like chemotherapy, work by poisoning fast-growing cells to kill the cancer. This also hurts healthy cells, causing side effects like hair loss and weakness. Anktiva is different. It is an immunotherapy that wakes up your body’s own immune cells; natural killer cells and T cells to hunt and destroy cancer cells themselves. It acts like a booster shot for your immune system, using a protein called IL-15 to make these cells multiply and remember how to fight cancer long-term. ImmunityBio is different from most companies because of 3 big unique things: 1. They wake up 3 kinds of fighter cells at the same time: • NK cells (natural killers) • CD8 T cells (main attackers) • CD4 T cells (helpers) These three work together like a basketball team. This makes the body remember the cancer for a long time (maybe years). 2. They have a special cell line called NK-92. → It’s like buying frozen pizza instead of making dough from scratch every time. Doctors can just thaw it and give it to any patient. No need to take cells from the sick kid, customize them, and make them super weak with hospital chemo (that’s what normal CAR-T does). 3. Their medicine Anktiva gives a long, steady boost to the immune cells. Older drugs (like IL-2) gave a short, crazy boost that made people very sick. Anktiva is seems safer, so far. Exciting to follow the development. Interview: Chris Cuomo (NewsNation) — “Killing Cancer”

Black Panther Capital

40,249 просмотров • 6 месяцев назад

Just a reminder: Kevin McKernan participated in the original Human Genome Project, and his video is featured at the Museum of Science, where he’s already made history. No one is more knowledgeable on this subject than him. Kevin McKernan is a prominent genomic scientist and entrepreneur. He served as the R&D lead for the Human Genome Project at the MIT Whitehead Institute for Biomedical Research. He founded Medicinal Genomics in 2011, where he pioneered the sequencing of the cannabis genome, making worldwide news as the first to publicly release a cannabis genome sequence. Previously, he was involved in developing next-generation sequencing technologies and founded Agencourt Biosciences, which advanced DNA sequencing methods used in various genomic projects. McKernan holds a degree from MIT and has authored numerous publications and patents in genomics, focusing on areas like DNA sequencing, microRNAs, and personalized medicine. His contributions have solidified his reputation as a leading expert in the field. What is amazing about his discovery is that it ties in with my work finding mRNA vaccines kill the bifidobacteria and finding of loss of bifidobacteria in invasive cancer BUT it also ties in with the independent findings on Covid spike affecting p53 by Wafik S. El-Deiry, MD, PhD, FACP . Imagine 3 different scientists with 3 different pathways coming to the same conclusions. This needs to be looked at …

sabine hazan md

25,437 просмотров • 9 месяцев назад